Hemophilia

Hemophilia is a genetic condition in which the blood-clotting process is slowed, resulting in prolonged bleeding from an injury. In severe cases, people with hemophilia spontaneously bleed when there is no obvious injury or severely bleed following a minor injury.

Quick Answer

What it is

Hemophilia is a genetic condition in which the blood-clotting process is slowed, resulting in prolonged bleeding from an injury. In severe cases, people with hemophilia spontaneously bleed when there is no obvious injury or severely bleed following a minor injury.

Key findings

  • Grade A: Factor VIII Levels (Desmopressin (DDAVP))
  • Grade A: von Willebrand Factor Levels (Desmopressin (DDAVP))

Safety

  • In severe cases, people with hemophilia spontaneously bleed when there is no obvious injury or severely bleed following a minor injury.
ℹ️ Quick Facts

Quick Facts: Hemophilia

  • Supplements Studied:1
1 supps · 2 outcomes

Evidence-Based Protocol

Supplement stack ranked by research quality

Limited Evidence

Primary Stack (Tier 1)

2000-4000 IU daily (monitor levels; target >40 ng/mL)

Supports bone health; hemophilia patients at high risk for osteoporosis; deficiency common

10 studies | 500 participants
1000-1200mg daily (from diet + supplements)

Essential for bone health; hemophilia patients have increased osteoporosis risk

8 studies | 400 participants

Supporting Stack (Tier 2)

As directed by hematologist based on iron studies

May be needed if chronic blood loss leads to iron deficiency anemia; test before supplementing

6 studies | 300 participants
1-2g EPA+DHA daily (moderate dose; discuss with hematologist)

Anti-inflammatory; may help with joint health; use with caution due to potential mild bleeding effect

4 studies | 150 participants
1500mg glucosamine + 1200mg chondroitin daily

May support joint health; hemophilic arthropathy is major complication

5 studies | 200 participants
500-1000mg daily

Supports collagen synthesis and wound healing; important for joint and tissue health

4 studies | 150 participants
500-1000mcg daily

Supports red blood cell production; may be important with chronic blood loss

4 studies | 150 participants
400-800mcg daily

Supports red blood cell production

4 studies | 150 participants
10-20 billion CFU daily

Supports gut health; may help with GI issues sometimes associated with hemophilia treatment

3 studies | 100 participants

How It Works

Hemophilia is a genetic bleeding disorder caused by deficiency of clotting factors (Factor VIII in Hemophilia A, Factor IX in Hemophilia B). This results in prolonged bleeding, especially into joints (hemarthrosis) and muscles. Without treatment, repeated joint bleeds lead to hemophilic arthropathy (chronic joint damage). Modern treatment with factor replacement or newer non-factor therapies (emicizumab) has transformed outcomes.

CRITICAL: Hemophilia requires lifelong management by a specialized hemophilia treatment center. Primary treatment includes:

Factor replacement therapy: On-demand (for bleeds) or prophylactic (regular infusions to prevent bleeds)
Non-factor therapies: Emicizumab (Hemlibra) for hemophilia A; other agents in development
Gene therapy: Emerging curative option for some patients
Physical therapy: Essential for joint health
Bleed management protocol: Know when and how to treat bleeds

SUPPLEMENTS TO AVOID OR USE WITH CAUTION:

Fish oil at high doses may slightly increase bleeding risk
Vitamin E at high doses may increase bleeding
Garlic supplements may increase bleeding
Ginkgo biloba may increase bleeding
NSAIDs (not a supplement but commonly used) should be avoided

SUPPORTIVE SUPPLEMENTS:

* Vitamin D and Calcium are important because hemophilia patients have significantly higher rates of osteoporosis (up to 70% have low bone density). This is due to limited weight-bearing exercise and chronic joint disease.

* Iron may be needed if chronic bleeding causes iron deficiency. Always test before supplementing.

* Glucosamine/Chondroitin may support joint health, which is the major long-term issue in hemophilia.

* Omega-3s (moderate dose) may help with joint inflammation, but use cautiously and discuss with your hematologist.

Expected outcomes: Supplements support overall health but do not replace factor therapy or hemophilia treatment. Work closely with your hemophilia treatment center.

Generated from peer-reviewed researchSchema v2.0

Detailed Outcomes

A
Factor VIII Levels
2-4 fold increase in factor VIII coagulant activity, allowing minor surgery in mild hemophilia A without factor concentrates.
largeImproves
A
von Willebrand Factor Levels
Up to 4-fold increase in vWF levels. Effective for von Willebrand disease Type I and some Type II variants.
largeImproves

Research Citations (54)

A Review of Desmopressin Use in Bleeding Disorders: An Unsung Hero?
(2025)
PMID: 40723839
Lithium-induced Nephrogenic Diabetes Insipidus with Efficacy of Desmopressin in Combination with Thiazide Diuretics and Non-steroidal Anti-inflammatory Drugs: A Case Report with a Review of the Literature.
(2024)
PMID: 37779064
Desmopressin, Misoprostol, nor Carboprost Affect Platelet Aggregability Following Traumatic Brain Injury and Aspirin.
(2024)
PMID: 38359679
Desmopressin use in major cardiac surgery is associated with renal impairment: a retrospective single-center analysis.
(2024)
PMID: 39375596
Safety and efficacy of desmopressin (DDAVP) in preventing hematoma expansion in intracranial hemorrhage associated with antiplatelet drugs use: A systematic review and metaanalysis.
(2024)
PMID: 38778788
Desmopressin (DDAVP) use in patients with von Willebrand disease: A single-centre retrospective review of test response and clinical outcomes.
(2023)
PMID: 37257847
Infection with SARS-CoV-2 may alter the half-life of desmopressin (DDAVP) in patients with central diabetes insipidus.
(2022)
PMID: 36240057
Desmopressin Stimulates Nitric Oxide Production in Human Lung Microvascular Endothelial Cells.
(2022)
PMID: 35327581
Desmopressin in canine mammary carcinoma: Comments on the importance of the administration route.
(2021)
PMID: 32700352
Safety of renal biopsy bleeding prophylaxis with desmopressin.
(2021)
PMID: 34590925

Related Conditions